Focus: Sagimet Biosciences is a clinical-stage biotech focused on fatty acid synthase (FAS) inhibitors targeting metabolic diseases, oncology, and infectious diseases. The company is publicly traded and headquartered in San Mateo, CA.
Profile data last refreshed 9h ago · AI intelligence enriched 2mo ago
Stable — net -1 jobs in 30d
0 added, 1 removed. Backfill posture.
Best fit for specialists (regulatory, clinical ops) seeking a focused platform bet in metabolic disease with near-term Phase 3 catalysts; less suitable for growth-phase generalists.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Sagimet Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Sagimet Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Citizens raises Sagimet stock price target to $29 on acne drug - Investing.com
Citizens raises Sagimet stock price target to $29 on acne drug Investing.com
Sagimet Biosciences Receives FDA 'Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients - The Manila Times
Sagimet Biosciences Receives FDA 'Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients The Manila Times
Sagimet Plans Acne Trial With About 800 Patients, 450 Expected Adolescents - Stock Titan
Sagimet Plans Acne Trial With About 800 Patients, 450 Expected Adolescents Stock Titan
FDA Approves Sagimet Biosciences' IND for Phase 3 Denifanstat Acne Study - Kalkine Media
FDA Approves Sagimet Biosciences' IND for Phase 3 Denifanstat Acne Study Kalkine Media
Sagimet Plans Phase 3 Trial for Potential Once-Daily Acne Treatment - Stock Titan
Sagimet Plans Phase 3 Trial for Potential Once-Daily Acne Treatment Stock Titan
Exclusive BAC Article: Sagimet Biosciences; China NDA Acceptance Denifanstat For Acne, 2nd Half 2026 U.S. Study Initiation, MASH Drug Combination, And Catalysts (NASDAQ:SGMT) - Seeking Alpha
Exclusive BAC Article: Sagimet Biosciences; China NDA Acceptance Denifanstat For Acne, 2nd Half 2026 U.S. Study Initiation, MASH Drug Combination, And Catalysts (NASDAQ:SGMT) Seeking Alpha
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo